PDE4A and cystic fibrosis: Ensifentrine has been shown to elevate cAMP levels in human neutrophils and in isogenic human cystic fibrosis bronchial epithelial cells expressing wt-CFTR (CFBE41o-WT), indicating its ability to inhibit PDE3 and PDE4 to promote airway relaxation (32, 33).